Arch Therapeutics Co-Founder Dr. Ellis-Behnke Speaks at 6th Annual CLINAM Nanomedicine Summit in Basel, Switzerland
July 23, 2013 09:50 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 23, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Co-Founder Rutledge Ellis-Behnke Delivers Keynote at Nanomaterials Technology Transfer Conference in Corfu, Greece
July 16, 2013 09:00 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 16, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Appoints Senior Management Team Members
July 08, 2013 09:00 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 8, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Introduces Experienced Directors and Executive Leadership
July 02, 2013 09:00 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jul 2, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), a life science company and developer of AC5™, a novel product aimed at...
Arch Therapeutics Effects Merger to Commence Operations as a Life Science Company
June 27, 2013 17:04 ET
|
Arch Therapeutics, Inc.
CAMBRIDGE, MA--(Marketwired - Jun 27, 2013) - Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company") is pleased to announce the closing of a reverse acquisition merger on June 26, 2013,...